Our results, although restricted in SLE, confirm the findings of Mullen et al. (2012) that anti-PS/PT antibodies may serve as a surrogate marker for unfavorable outcome in TIA and may represent a subsequent stage in disease evolution in lupus patients. The gene discussed is PRB2; the disease is systemic lupus erythematosus.